Quick Answer
CUMBERLAND PHARMACEUTICALS INC reported Operating Income Loss of -$2.79 million for the year ending 2025.
- CUMBERLAND PHARMACEUTICALS INC showed an increase of +56.6% in Operating Income Loss from 2024 to 2025.
- This data is from CUMBERLAND PHARMACEUTICALS INC's annual report (Form 10-K), filed with the SEC on March 9, 2026.
- XBRL data for this metric is available from 2009 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 17 years of available data (2009 to 2025), CUMBERLAND PHARMACEUTICALS INC's Operating Income Loss has declined by 148.3%.
- Historical annual values: Fiscal year 2025: -$2.79 million | Fiscal year 2024: -$6.43 million | Fiscal year 2023: -$9.55 million | Fiscal year 2022: -$5.70 million | Fiscal year 2021: -$7.68 million | Fiscal year 2020: -$6.38 million | Fiscal year 2019: -$9.29 million | Fiscal year 2018: -$11.17 million | Fiscal year 2017: -$4.08 million | Fiscal year 2016: -$1.43 million | Fiscal year 2015: $1.11 million | Fiscal year 2014: $3.56 million | Fiscal year 2013: -$3.80 million | Fiscal year 2012: $8.82 million | Fiscal year 2011: $9.85 million | Fiscal year 2010: $6.50 million | Fiscal year 2009: $5.78 million.
- Data sourced from SEC EDGAR public filings as of June 23, 2026.
Last verified: